Bradley Cole

Dec 10, 2018

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant.

Breaking News

Bradley Cole

Studies of Chinese Pregnancies Delve Into Underlying Genetic Contributors to Diseases and Conditions

Verily-led Consortium Receives $4.8M in NIH Funding to Build Data Analysis Platform

Bionano Genomics Preliminary Q3 Revenues Below Guidance

10x Genomics' Share Price Tumbles as Preliminary Q3 Revenues Show 1 Percent Drop

Clock.bio Raises $5.3M in Seed Funding to Support Human Longevity Research